Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 3Pancreatic Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Kidney Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Metastatic Urothelial Cancer 1Melanoma 1Lung Diseases 1Glioblastoma 1Esophageal Neoplasms 1Erythrocytosis, Familial, 4 1Cholangiocarcinoma 1Advanced Solid Tumors 1Advanced Non-Small Cell Lung Cancer 1

Interventions

cabozantinib 5Nivolumab 4Ipilimumab 4Axitinib 4pembrolizumab 3Blood Specimen Collection 3zimberelimab 2atezolizumab 2Surveys and Questionnaires 2Sunitinib 2Irinotecan 2temsirolimus 1spartalizumab 1salicylhydroxamic acid 1palbociclib 1orellanine 1olaparib 1liposomal doxorubicin 1lenvatinib 1gallium Ga 68 dotatate 1fludarabine 1brodalumab 1belzutifan 1aldesleukin 1adagrasib 1Vincristine 1Temozolomide 1Taxes 1Selenomethionine 1Ropivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × zimberelimab × 90 days × Clear all
NCT05536141 2026-06-01

ARC-20

Arcus Biosciences, Inc.

Phase 1 Recruiting
362 enrolled
Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡